Kemény Kata Kira, Kozinszky Zoltan, Altorjay Ábel T, Kolcsár Bálint, Surányi Andrea, Ducza Eszter
Department of Pharmacodynamics and Biopharmacy, Faculty of Pharmacy, University of Szeged, H-6726 Szeged, Hungary.
Department of Obstetrics and Gynecology, Albert Szent-Györgyi Medical School, University of Szeged, H-6725 Szeged, Hungary.
J Clin Med. 2024 Jul 31;13(15):4490. doi: 10.3390/jcm13154490.
Obesity and overweight are also becoming more prevalent among women of childbearing age and pregnant women. In maternal obesity, the activation of metabolic, inflammatory, and oxidative stress pathways is proven, which appears to be a key step in the pathological changes observed in placental and uterine function. Several recent studies have evidenced that aquaporins (AQPs) are critical players in adipose tissue biology and are involved in the onset of obesity. Our studies aimed to investigate the changes in placental volume and vascularization and measure the AQP5 expression and total antioxidant capacity (TAC) in the placenta and uterus tissues in obese and typical-weight mothers. We also aim to measure the AQP5 plasma concentration. We found AQP5 dominance in the uterus and plasma at 34 weeks of normal pregnancy. The placental volume increased and the vascularization decreased in obese mothers compared to the control. The AQP5 expression increased in the uterus of the obese group and did not change in the placenta. The TAC decreased in the plasma of overweight mothers. We hypothesize that increased AQP5 expression prolongs the length of pregnancy and inhibits the onset of contractions. Based on our findings, we can develop diagnostic tests and provide new targets for tocolytic drug development.
肥胖和超重现象在育龄妇女和孕妇中也日益普遍。在孕产妇肥胖中,代谢、炎症和氧化应激途径的激活已得到证实,这似乎是胎盘和子宫功能病理变化中的关键一步。最近的几项研究表明,水通道蛋白(AQP)在脂肪组织生物学中起关键作用,并与肥胖的发生有关。我们的研究旨在调查肥胖母亲和正常体重母亲胎盘体积和血管形成的变化,并测量胎盘和子宫组织中水通道蛋白5(AQP5)的表达及总抗氧化能力(TAC)。我们还旨在测量血浆中AQP5的浓度。我们发现,在正常妊娠34周时,子宫和血浆中AQP5占主导地位。与对照组相比,肥胖母亲的胎盘体积增加而血管形成减少。肥胖组子宫中AQP5的表达增加,而胎盘中未发生变化。超重母亲血浆中的TAC降低。我们推测,AQP5表达增加会延长妊娠期并抑制宫缩的开始。基于我们的研究结果,我们可以开发诊断测试,并为宫缩抑制剂的研发提供新的靶点。